Skip to main content
SpringerLink
Log in

Autologous hematopoietic stem cell transplantation for lymphoma: An evaluation of grafts source and minimal residual disease

  • Published:
Chinese Journal of Cancer Research

Abstract

Objective: To determine whether the source of autologous hematopoietic stem cells altered the clinical outcomes of patients undergoing high dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) for aggressive lymphoma and to study the problem of minimal residual disease (MRD). Methods: 14 lymphoma patients who had lymphoma with high risk factors, relapsed lymphoma or refractory lymphoma received autologous bone marrow transplantation (ABMT). 14 lymphoma patients who were similar to ABMT group received autologous peripheral blood stem cells transplantation (APBSCT). Regimen of CBV (cyclophos phamide 50∼60 mg/kg/d×2 d, carmustine 15 mg/kg/d×1 d, etoposide 45∼60 mg/kg/d×1 d) was received by all the patients as conditioning regimen in the transplant pretreatment followed by ABMT or APBSCT. Autologous peripheral blood stem cell (APBSC) was mobilized by CTX 2g∼3g/m2/d×2 d iv and G-CSF 5 µg/kg/d for five to seven days. MRD was continually supervised by PCR in bone marrow before and after transplantation. Cellular immunocyte function, such as natural killer cell (NK), CD3, CD4, CD8 and sIL-2R was tested before and twenty days after transplantation. Results: In ABMT group, the median time for hematopoietic recovery of absolute neutrophilia counts ≥0.5×109/L and platelet counts ≥20×109/L was +18 days and +20 days respectively. In contrast, the APBSCT group was both at 12 days. Patients who have undergone ABMT all got complete remission (CR), while 81.8% patients in APBSCT group got CR. The 3-year disease free survival (DFS) in APBSCT and ABMT group was 75% and 72.7% respectively (P>0.05). The mean days of immunity recovering in APBSCT was ±20 days. After transplantation, MRD in 11 patients were positive, in whom 6 patients died. Conclusion: Aggressive lymphoma patients’ hemapoiesis recovered more rapidly in APBSCT group than that in ABMT group, but 3-year DFS had no statistical difference. Patients positive for IgH/TCR-γ by molecular PCR analysis had poor DFS. Molecur monitoring of MRD using PCR techniques seems to represent a reliable prognostic indicator. Immunotherapy in the patients whose bone morrow was positive for MRD post-AHSCT may intensify remission and reduce relapse rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gisselbrecht C. Autologous stem cell transplantation in aggressive non-Hodgkin’s lymphoma [J]. Recent Results Cancer Res 1998; 144:15–26.

    PubMed  CAS  Google Scholar 

  2. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol — a grouped’ Etude des lymphomas de l’ Adulte study [J]. J Clin Oncol 2000; 18:3025–30.

    PubMed  CAS  Google Scholar 

  3. Galimberti S, Marasca F, Caracciolo F, et al. Minimal residual disease. The role of molecular monitoring in autotransplantation for non-Hodgkin’s lymphoma [J]. Bone Marrow Transplantation 2000; 29:581–7.

    Article  Google Scholar 

  4. Negrin RS, Blume KG. The use of the polymerase chain reaction for the detection of minimal residual malignant disease [J]. Blood 1991; 78:255–8.

    PubMed  CAS  Google Scholar 

  5. Liu Kaiyan. Current status of CBT. The Second International Symposiums in Lymphoma. 2004; 14–5.

  6. Stiff PJ, Dahlberg S, Forman SJ, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin’s lymphoma: Value of augmented preparative regimens — a southwest oncology group trial [J]. J Clin Oncol 1998; 16:48–55.

    PubMed  CAS  Google Scholar 

  7. Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy [J]. Blood 1993; 81:2031–5.

    PubMed  CAS  Google Scholar 

  8. To LB, Roberts MM, Haylock DN, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants [J]. Bone Marrow Transplant 1992; 9:277–84.

    PubMed  CAS  Google Scholar 

  9. Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor [J]. Blood 1993; 81:3158–63.

    PubMed  CAS  Google Scholar 

  10. Majolino I, Pearce R, Taghipour G, et al. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin’s and non-Hodgkin’s lymphomas: a new matched-pair analysis of the European group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation [J]. J Clin Oncol 1997; 15:509–17.

    PubMed  CAS  Google Scholar 

  11. Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin’s lymphoma: results of a randomized trial evaluating graft source and minimal residual disease [J]. J Clin Oncol 2002; 20:2344–52.

    Article  PubMed  Google Scholar 

  12. Jonkhoff AR, De Kreuk AM, Franschman G, et al. Graneulocyte colony-stimulating factor mobilized whole blood containing over 0.3×106/kg CD34+ cells is a sufficient graft in autologous transplantation in relapsed non-Hodginkin’s lymphoma [J]. Br J Haematol 2002; 118:90–100.

    Article  PubMed  CAS  Google Scholar 

  13. Ashihara E, Shimazaki C, Okano A, et al. Infusion of a high number of CD34+ cells provides a rapid hematopoietic recovery and cost savings in autologous peripheral blood stem cell transplantation [J]. Jpn J Clin Oncol 2002; 32:135–9.

    Article  PubMed  Google Scholar 

  14. Liu HC, Yao SQ, Lou FD, et al. The clinical research in leukemia and lymphoma undergoing ABMT and APBSCT. J Chin Hematol 1996; 17:548–9.

    Google Scholar 

  15. Vivancos P, Granena A Jr, Sarra J, et al. Treatment with interlukin-2 (IL-2) and interferon (IFN (alpha 2b)) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse [J]. Bone Marrow Transplant 1999; 23:169–72.

    Article  PubMed  CAS  Google Scholar 

  16. Nagler A, Ackerstein A, Or R, et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation [J]. Blood 1997; 11:3951–9.

    Google Scholar 

  17. Voso MT, Martin S, Hohaus S, et al. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation [J]. Bone Marrow Transplant 2000; 25:957–64.

    Article  PubMed  CAS  Google Scholar 

  18. Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma [J]. Blood 1999; 94:3325–33.

    PubMed  CAS  Google Scholar 

  19. Favrot MC, Herve P. Detection of minimal malignant cell infiltration in the bone marrow of patients with solid tumors, non-Hodgkin lymphomas and leukaemias [J]. Bone Marrow Transplant 1987; 2:117–22.

    PubMed  CAS  Google Scholar 

  20. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after auto-logous hematopoietic stem cell transplantation [J]. Blood 1998; 92:1471–90.

    PubMed  CAS  Google Scholar 

  21. Reichart VL, Okada CY, Liso A, et al. Idiotype vaccination on using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma and lymphomas — a feasibility study [J]. Blood 1999; 93:2411–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Shanxi Cancer Hospital, 030013, Taiyuan

    Hou Shu-ling, Zhang Qiao-hua, Han Wei-e, Gui Wei & Wang Yu-luan

Authors
  1. Hou Shu-ling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhang Qiao-hua
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Han Wei-e
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gui Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wang Yu-luan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhang Qiao-hua.

Additional information

Biography: HOU Shu-ling (1967–); female, master of medicine, associate professor, Shanxi Cancer Hospital, majors in hemotology.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hou, Sl., Zhang, Qh., Han, We. et al. Autologous hematopoietic stem cell transplantation for lymphoma: An evaluation of grafts source and minimal residual disease. Chin. J. Cancer Res. 17, 217–223 (2005). https://doi.org/10.1007/s11670-005-0044-z

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11670-005-0044-z

Key words

CLC number

Search

Navigation